IPO Advisory
In-depth, experienced and seamless execution throughout the IPO Process.
Mahamaya Lifesciences IPO is a book build IPO listing on BSE SME exchange. The company is based in New Delhi and caters to Chemical - Pesticides sector. Oneview Corporate Advisors Private is the merchant banker of Mahamaya Lifesciences IPO. It is a SME UPCOMING IPO which filed its Draft Red Herring Prospectus (DRHP) on 27th February 2025.
Mahamaya Lifesciences IPO posted revenues of Rs 294.30 crores and PAT of Rs 14.82 crores in FY25 on annualised basis.Financial results of Mahamaya Lifesciences IPO based on restated financials as per prospectus and IPO review parameters can be referred to below.
Mahamaya Lifesciences IPO PAT Margin is 5.07%, ROCE (Return on Capital Employed) is 23.04% as per latest financial. The below table shows Mahamaya Lifesciences IPO Key Performance Indicators (KPI) as mentioned in company’s prospectus.
The market Capitalisation of Mahamaya Lifesciences IPO is Rs [●] crores at the time of IPO and other IPO valuation metrics of this IPO is mentioned below.
The Mahamaya Lifesciences IPO prospectus highlights an Return on Equity (ROE) of 15%, Return on Assets (ROA) of 12%, and an EBITDA Margin of 18%, showcasing financial performance.
Profitability ratios like Return on Equity (ROE), Return on Assets (ROA), and Net Profit Margin shows Mahamaya Lifesciences IPO financial report. Analysing these metrics can provide insights into the company’s efficiency, profitability, and long-term growth potential.
The post-IPO market capitalisation of Mahamaya Lifesciences IPO is ₹[●] Cr, based on the issue price and share structure. It helps investors gauge the company’s valuation and compare it with industry peers before investing.
The Mahamaya Lifesciences IPO has a Price-to-Earnings (PE) ratio of [●], indicating valuation compared to industry peers. It helps investors determine if the stock is overvalued or undervalued compared to its earnings and industry peers.
Mahamaya Lifesciences IPO reported revenue of ₹294.30 Cr in the latest fiscal year, showing business performance, on annualised basis. Revenue figures from Mahamaya Lifesciences IPO provide insights into sales growth, market demand, and business scalability.
Mahamaya Lifesciences recorded an EBITDA of ₹ 27.24 Cr., reflecting operational efficiency. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortisation) measures operational profitability.
Mahamaya Lifesciences Profit After Tax (PAT) is ₹14.82 Cr, reflecting earnings growth. Profit After Tax (PAT) reflects the company’s actual earnings after all expenses, taxes, and deductions
Revenue:
₹ 292.46 Cr.
EBITDA Margin:
9.31
%
Net Worth: ₹ 45.87 Cr.
Market Capitalisation:
[●]
P/E:
[●]
P/BV: [●]
EV/EBITDA: [●]
Mahamaya Lifesciences operates in Chemical - Pesticides and . The Issue is listed on BSE SME in Apr, 2025. Mahamaya Lifesciences IPO size was with Issue price of .
Merchant Banker(s) of Mahamaya Lifesciences IPO: Oneview Corporate Advisors Private Limited
Mahamaya Lifesciences IPO subscription was X. IPO subscription refers to applications received in an IPO by each quota, i.e., QIB, Retail, and NII. In some IPOs, Eligible employee quota and shareholder’s quota are also present. Learn more about IPO subscriptions here.
Mahamaya Lifesciences IPO listed at a listing price of against the offer price of .
The current market price of Mahamaya Lifesciences is .
Why Us?
